OcugenOCGN
OCGN
About: Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Employees: 95
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
147% more call options, than puts
Call options by funds: $351K | Put options by funds: $142K
26% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 23
6% less funds holding
Funds holding: 110 [Q1] → 103 (-7) [Q2]
8% less capital invested
Capital invested by funds: $54.2M [Q1] → $49.7M (-$4.43M) [Q2]
8.7% less ownership
Funds ownership: 26.27% [Q1] → 17.57% (-8.7%) [Q2]
15% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 39
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
573%
upside
Avg. target
$7
573%
upside
High target
$7
573%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Daniil Gataulin | 573%upside $7 | Buy Maintained | 4 Aug 2025 |
HC Wainwright & Co. Swayampakula Ramakanth | 573%upside $7 | Buy Reiterated | 24 Jun 2025 |
Financial journalist opinion
Based on 8 articles about OCGN published over the past 30 days
Positive
Zacks Investment Research
10 hours ago
Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know
Ocugen (OCGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
1 week ago
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reviewed the study design, endpoints and planned statistical analysis of the ongoing pivotal confirmatory OCU410ST Phase 2/3 GARDian3 clinical trial for Stargardt disease and provided acceptability of a single U.S.-based trial for submission of a Marketing Authorization Application (MAA).
Neutral
GlobeNewsWire
2 weeks ago
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management firm, for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company's common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period.
Neutral
GlobeNewsWire
2 weeks ago
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with Janus Henderson Investors, a global asset management firm, to purchase 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant in a registered direct offering. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company's common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period.
Positive
The Motley Fool
3 weeks ago
Ocugen (OCGN) Q2 Revenue Jumps 20%
Ocugen (OCGN) Q2 Revenue Jumps 20%
Neutral
Seeking Alpha
3 weeks ago
Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript
Ocugen, Inc. (NASDAQ:OCGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Arun Upadhyay - Chief Scientific Officer and Head of Research & Development Huma Qamar - Chief Medical Officer Ramesh Ramachandran - Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer Shankar Musunuri - Co-Founder, CEO & Chairman Tiffany J. Hamilton - AVP & Head of Corporate Communications Conference Call Participants Boris Peaker - Unidentified Company Daniil V.
Negative
Zacks Investment Research
3 weeks ago
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.04 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trial Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial and on track for 2026 BLA filing OrthoCellix reverse merger intended to unlock the value of NeoCart/regenerative cell therapies and enable the Company to focus capital on modifier gene therapy platform Signed binding term sheet for exclusive Korean rights to OCU400 with upfront fees and near-term development milestone payments totaling up to $11 million MALVERN, Pa.
Neutral
GlobeNewsWire
1 month ago
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced updates to its Retina Scientific Advisory Board (SAB) and Executive Leadership Team to enhance external guidance from key opinion leaders and strengthen the Company's internal expertise in critical functions and as it pursues its goal of three BLAs in the next three years.
Neutral
GlobeNewsWire
1 month ago
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies).
Charts implemented using Lightweight Charts™